Yes, the orphan drug designation will get some some revenue, not sure how they will get the ASD component monetized though, I assume we would require a larger sample size to get this moving and it would be costly.
- Forums
- ASX - By Stock
- NTI
- Ann: Phase II/III autism trial shows further benefits
Ann: Phase II/III autism trial shows further benefits, page-10
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
|
|||||
Last
7.1¢ |
Change
-0.001(1.39%) |
Mkt cap ! $72.23M |
Open | High | Low | Value | Volume |
7.2¢ | 7.4¢ | 7.1¢ | $38.11K | 530.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 193384 | 7.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 17269 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 193384 | 0.071 |
8 | 477708 | 0.070 |
3 | 237492 | 0.069 |
2 | 89000 | 0.068 |
1 | 30000 | 0.067 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 17269 | 1 |
0.073 | 40000 | 1 |
0.075 | 35347 | 1 |
0.078 | 176655 | 2 |
0.079 | 264102 | 2 |
Last trade - 15.56pm 21/08/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |